中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
Evaluation and Analysis of Drug-Use in Hospitals of China
2015年
11期
1452-1453,1454
,共3页
替格瑞洛%PCI%支架内血栓%临床疗效
替格瑞洛%PCI%支架內血栓%臨床療效
체격서락%PCI%지가내혈전%림상료효
Ticagrelor%PCI%Stent thrombosis%Clinical efficacy
目的：探讨替格瑞洛治疗动脉介入治疗（ percutaneous coronary intervention ，PCI）术后支架内血栓的疗效和安全性。方法：选择2013年1月—2015年1月收治的110例行PCI术后支架内血栓患者，按随机数字表法分为对照组和观察组各55例。对照组患者术后采取常规治疗，观察组患者给予替格瑞洛治疗，观察2组支架内血栓形成情况。结果：对照组患者急性支架内血栓、亚急性支架内血栓、晚期支架血栓、极晚期支架血栓形成率为21.82％、23.64％、14.55％、7.27％，观察组为7.27％、9.09％、3.64％、0.00％，观察组患者各种血栓形成率均明显低于对照组，差异有统计学意义（ P＜0.05）；2组患者治疗过程中均无室性停搏、出血、呼吸困难等不良反应发生。结论：PCI术后支架内血栓患者采用替格瑞洛治疗，安全、可靠，效果显著，值得临床推广。
目的：探討替格瑞洛治療動脈介入治療（ percutaneous coronary intervention ，PCI）術後支架內血栓的療效和安全性。方法：選擇2013年1月—2015年1月收治的110例行PCI術後支架內血栓患者，按隨機數字錶法分為對照組和觀察組各55例。對照組患者術後採取常規治療，觀察組患者給予替格瑞洛治療，觀察2組支架內血栓形成情況。結果：對照組患者急性支架內血栓、亞急性支架內血栓、晚期支架血栓、極晚期支架血栓形成率為21.82％、23.64％、14.55％、7.27％，觀察組為7.27％、9.09％、3.64％、0.00％，觀察組患者各種血栓形成率均明顯低于對照組，差異有統計學意義（ P＜0.05）；2組患者治療過程中均無室性停搏、齣血、呼吸睏難等不良反應髮生。結論：PCI術後支架內血栓患者採用替格瑞洛治療，安全、可靠，效果顯著，值得臨床推廣。
목적：탐토체격서락치료동맥개입치료（ percutaneous coronary intervention ，PCI）술후지가내혈전적료효화안전성。방법：선택2013년1월—2015년1월수치적110례행PCI술후지가내혈전환자，안수궤수자표법분위대조조화관찰조각55례。대조조환자술후채취상규치료，관찰조환자급여체격서락치료，관찰2조지가내혈전형성정황。결과：대조조환자급성지가내혈전、아급성지가내혈전、만기지가혈전、겁만기지가혈전형성솔위21.82％、23.64％、14.55％、7.27％，관찰조위7.27％、9.09％、3.64％、0.00％，관찰조환자각충혈전형성솔균명현저우대조조，차이유통계학의의（ P＜0.05）；2조환자치료과정중균무실성정박、출혈、호흡곤난등불량반응발생。결론：PCI술후지가내혈전환자채용체격서락치료，안전、가고，효과현저，치득림상추엄。
OBJECTIVE:To probe into the efficacy and safety of ticagrelor therapy in treatment of stent thrombosis after PCI.METHODS:110 cases with stent thrombosis after PCI admitted into the hospital from Jan .2013 to Jan. 2015 were divided into the control group and observation group via the random number table , with 55 cases in each group.The control group received the conventional treatment after surgery , the observation group were treated with ticagrelor therapy , stent thrombosis of two groups were observed .RESULTS: The acute stent thrombosis , subacute stent thrombosis , late stent blood and extremely late stent thrombosis rate in control group were respectively 21.82%, 23.64%, 14.55%and 7.27%, while in observation group were respectively 7.27%, 9.09%, 3.64%and 0.00%;the thrombosis rates of observation group were significantly lower than that of the control group , with statistically significant difference ( P<0.05) .There were no adverse reactions like ventricular arrest , bleeding and dyspnea during the treatment in two group of patients .CONCLUSIONS: The ticagrelor therapy in treatment of patients with stent thrombosis after PCI is safe and reliable , which has significant effect and is worthy of clinical promotion .
